STAT6 deficiency also corrected liver injury and inflammation induced by alpha-galactosylceramide, a specific agonist for invariant natural killer T (iNKT) cells evaluated in the context of treatment for liver cancer (Wang et al., 2013). This evidence concerns the gene STAT6 and liver cancer.